AstraZeneca launches health-tech business, Evinova
Betsy Goodfellow | November 21, 2023 | News story | Business Services | AstraZeneca, Pharmacy, health-tech
AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is hoped will become a leading provider of digital health solutions for healthcare professionals, regulators and patients.
The new business has long-term backing from AstraZeneca as well as strategic collaborations with Parexel and Fortrea, both of which have entered into agreements to offer Evinova digital health solutions to their wider customer bases. Evinova is also partnering with Accenture and Amazon Web Services in order to accelerate the industry adoption and expand the global reach of its products.
It is intended that Evinova will “prioritise bringing to market established and scaled digital technology solutions already being used by AstraZeneca to optimise clinical trial design and delivery,” according to AstraZeneca’s press release.
The business aims to reduce the time and cost of developing new medicines while also bringing care closer to home for patients and reducing burden on health systems.
Cristina Duran, president of Evinova, commented: “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community. We believe this will help propel the sector forward in digital health, as we know healthcare professionals and regulators need digital solutions that work across pharma and support patients broadly. Coming from within the sector and with proven experience, Evinova will be uniquely placed to deliver science-based, evidence-led and human experience-driven solutions with the aim of improving patient experience and outcomes.”
Betsy Goodfellow
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
